Table 2

Improvement of a clinical risk model for DSPN by six biomarkers of subclinical inflammation associated with incident DSPN

Clinical risk model*Clinical risk model + MCP-3/CCL7, MIG/CXCL9, IP-10/CXCL10, DNER, CD40, and TNFRSF9
C statistic (95% CI)0.748 (0.698; 0.799)0.783 (0.735; 0.830)
ΔC statistic (95% CI)Reference0.034 (0.008; 0.060)
 PN/A0.011
Category-free net reclassification index (95% CI)Reference0.352 (0.154; 0.551)
 PN/A<0.001
Integrated discrimination index (95% CI)Reference0.049 (0.027; 0.071)
 PN/A2 × 10−5
  • N/A, not applicable.

  • *The clinical risk model includes age, sex, waist circumference, height, hypertension, total cholesterol, HbA1c, alcohol intake, smoking, physical activity, use of lipid-lowering drugs, use of nonsteroidal anti-inflammatory drugs, estimated glomerular filtration rate, prevalent myocardial infarction, and neurological conditions that might cause nerve damage (i.e., all covariates from the fully adjusted model, see Table 1). The same clinical risk model was used in a previous KORA F4/FF4 analysis that was based on a slightly larger study sample (16).